Wouter Plattel
dr.
As a hematologist I am always looking for new development that might improve patient care. My main research focus is on patients with Hodgkin lymphoma and multiple myeloma. I am involved in both translational and clinical studies. In cooperation with the Pathology, I am active in the field of biomarkers, such as TARC in Hodgkin lymphoma. For the design, development and execution of clinical trials, I am an active member of both international (EORTC) and national (HOVON) organizations. For example, I am the national PI of the EORTC COBRA trial in Hodgkin lymphoma. Moreover, I am co-PI of the translational research in two international trials. In addition, I am part of the Dutch guideline writing committee for Hodgkin lymphoma. In myeloma, I am investigating innovative treatment options to improve outcome.
Low Mutational Burden of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren’s Syndrome
Published in: Cancers
Access to document
10.3390/cancers14041010
document
Patients with primary Sjogren’s syndrome (pSS) are at risk of developing extranodal marginal zone lymphoma (ENMZL) of the mucosa-associated lymphoid tissue (MALT) in the parotid glands. Unlike recurrent genomic aberrations observed in MALT lymphoma, which were not associated with pSS (non-pSS), it is unknown which somatic aberrations underlie the development of pSS-associated MALT lymphomas. Whole-exome sequencing was performed on 17 pSS-associated MALT lymphomas. In total, 222 nonsynonymous somatic variants affecting 182 genes were identified across the 17 cases. The median number of variants was seven (range 2-78), including...
Johanna A A Bult, Jessica R Plaça, Erlin A Haacke, M Martijn Terpstra, Gwenny M Verstappen, Frederik K L Spijkervet, Frans G M Kroese, Wouter J Plattel, Joost S P Vermaat, Hendrika Bootsma, Bert van der Vegt, Arjan Diepstra, Anke van den Berg, Klaas Kok, Marcel Nijland
Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis
Published in: Leukemia & lymphoma
Access to document
10.1080/10428194.2021.1957865
document
This systematic review and meta-analysis aimed to determine the effectiveness of brentuximab vedotin (BV) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) in the clinical practice setting using most recent results. A total of 32 observational studies reporting on treatment patterns, overall response rate (ORR), complete response (CR) rate, progression-free survival (PFS), overall survival (OS), and adverse events were found. After four cycles, a random-effect model yielded pooled ORR and CR rates of 62.6% (95% confidence interval (CI): 56.0-68.9; I-2 = 9.7%) and 32.9% (95% CI, 20.8-46.3, I-2 =...
Wouter J. Plattel, Aurore Bergamasco, Fabrizio Trinchese, Francois Gavini, Nawal Bent-Ennakhil, Athanasios Zomas, Genaro Castillon, Teigna Arredondo-Bisono, Tiffany Cristarella, Yola Moride, Bastian von Tresckow
Low Mutational Burden of Extra Nodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren’s Syndrome
Published in: Blood
Access to document
10.1182/blood-2021-153130
Johanna A. A. Bult, Jessica R. Placa, Erlin A. Haacke, Gwenny M. Verstappen, Frederik K. L. Spijkervet, Frans G. M. Kroese, Wouter J. Plattel, Joost S. P. Vermaat, Hendrika Bootsma, Bert Van der Vegt, Arjan Diepstra, Anke Van Den Berg, Klaas Kok, Marcel Nijland
Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study
Published in: Blood
Access to document
10.1182/bloodadvances.2021004295
document
In 2017, the European Medicines Agency approved rituximab biosimilars (R-biosimilars) for treatment of diffuse large B-cell lymphoma (DLBCL). Thereafter, the Netherlands was one of the first countries to implement R-biosimilars, given lower costs compared with rituximab originator (R-originator). This study’s objective was to investigate whether overall survival (OS) of patients with DLBCL receiving R-biosimilars is similar to patients treated with R-originator. DLBCL patients >18 years, diagnosed between 2014 and 2018, who received at least 1 cycle of rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) were identified...
Mirian Brink, Xaver U. Kahle, Joost S. P. Vermaat, Josee M. Zijlstra, Martine Chamuleau, Marie Jose Kersten, Mujde Durmaz, Wouter J. Plattel, Pieternella J. Lugtenburg, Wendy Stevens, Rogier Mous, Elisabeth G. E. de Vries, Marjolein W. M. van der Poel, Prashant V. Nannan Panday, Gerwin Huls, Tom van Meerten, Marcel Nijland
Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients
Published in: Journal of the National Cancer Institute
Access to document
10.1093/jnci/djaa194
document
BACKGROUND: Few studies have examined the impact of treatment-related morbidity on long-term, cause-specific mortality in Hodgkin lymphoma (HL) patients. METHODS: This multicenter cohort included 4919 HL patients, treated before age 51 years between 1965 and 2000, with a median follow-up of 20.2 years. Standardized mortality ratios, absolute excess mortality (AEM) per 10 000 person-years, and cause-specific cumulative mortality by stage and primary treatment, accounting for competing risks, were calculated. RESULTS: HL patients experienced a 5.1-fold (AEM = 123 excess deaths per 10 000 person-years) higher risk of death due to causes...
Simone de Vries, Michael Schaapveld, Cécile P.M. Janus, Laurien A. Daniëls, Eefke J. Petersen, Richard W.M. van der Maazen, Josée M. Zijlstra, Max Beijert, Marten R. Nijziel, Karijn M.S. Verschueren, Leontien C.M. Kremer, Anna M. van Eggermond, Pieternella J. Lugtenburg, Augustinus D.G. Krol, Judith M. Roesink, Wouter J. Plattel, Dick Johan van Spronsen, Gustaaf W. van Imhoff, Jan Paul de Boer, Berthe M.P. AlemanFlora E. van Leeuwen